Increased risk of lomitapide adverse effects, particularly hepatotoxicity.
Lomitapide is contraindicated with inhibitors of CYP3A4.
Source: G&G 14e · p742
Statin · Hyperlipidaemia
Lomitapide inhibits microsomal triglyceride transfer protein (MTP), an enzyme essential for the lipidation and assembly of apolipoprotein B-containing lipoproteins (VLDL in the liver and chylomicrons in the intestine). By blocking MTP, it prevents VLDL secretion from hepatocytes, reducing circulating LDL cholesterol by 40-50% — even in patients with homozygous familial hypercholesterolemia who have no functional LDL receptors. Its use is restricted to homozygous FH because MTP inhibition causes hepatic triglyceride accumulation and steatosis, requiring regular liver monitoring and a strict low-fat diet.
Increased risk of lomitapide adverse effects, particularly hepatotoxicity.
Lomitapide is contraindicated with inhibitors of CYP3A4.
Source: G&G 14e · p742
Drug interaction classified as: synergy
Source: DDInter
Drug interaction classified as: synergy
Source: DDInter
Drug interaction classified as: synergy
Source: DDInter
Drug interaction classified as: synergy
Source: DDInter
Drug interaction classified as: synergy
Source: DDInter
Drug interaction classified as: synergy
Source: DDInter
Drug interaction classified as: synergy
Source: DDInter
Drug interaction classified as: synergy
Source: DDInter
Drug interaction classified as: synergy
Source: DDInter
Drug interaction classified as: synergy
Source: DDInter
Increased plasma concentrations of statins and their active metabolites, leading to an increased risk of myopathy and rhabdomyolysis.
Consider using pravastatin, fluvastatin, or rosuvastatin, as they are not extensively metabolized by CYP3A4. Carefully weigh the benefits against the risk of myopathy.
Source: DDInter
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e, Katzung·Verified: 2026-05-10 · House clinical team